UNIVERSITY BIRMINGHAM University of Birmingham Research at Birmingham

Protocol for the Tessa Jowell BRAIN MATRIX Platform Study

Watts, C.; Savage, J.; Patel, A.; Mant, R.; Wykes, V.; Pohl, Ute; Bulbeck, Helen; Apps, J.; Sharpe, R.; Thompson, Gerard; Waldman, Adam; Ansorge, Olaf; Billingham, L.; Watts, C.

DOI: 10.1101/2022.07.29.22277991

License: Creative Commons: Attribution (CC BY)

Document Version Other version

Citation for published version (Harvard):

Watts, C, Savage, J, Patel, A, Mant, R, Wykes, V, Pohl, U, Bulbeck, H, Apps, J, Sharpe, R, Thompson, G, Waldman, A, Ansorge, O, Billingham, L & Watts, C 2022 'Protocol for the Tessa Jowell BRAIN MATRIX Platform Study' medRxiv. https://doi.org/10.1101/2022.07.29.22277991

Link to publication on Research at Birmingham portal

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

•Users may freely distribute the URL that is used to identify this publication.

•Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.

•User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?) •Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

BRAIN MATRIX

1 Protocol for the Tessa Jowell BRAIN MATRIX Platform Study

- 2
- Colin Watts^{1†,2}, Joshua Savage³, Amit Patel³, Rhys Mant³, Victoria Wykes^{1,2}, Ute Pohl², Helen Bulbeck⁴, John
 Apps³, Rowena Sharpe³, Gerard Thompson⁵, Adam Waldman⁵, Olaf Ansorge⁶, Lucinda Billingham³ and the
- 5 TJBM Investigators*
- 6
- [†] Corresponding author contact details:
- 8 Professor Colin Watts. Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston,
 9 Birmingham. UK. Email: C.Watts.2@bham.ac.uk

10

11 *Additional Investigators of the BRAIN MATRIX study are listed in Supplementary Appendix 1.

12

- 13 ¹ Institute of Cancer and Genomic Sciences, University of Birmingham, Edgbaston, Birmingham. UK
- 14 ² University Hospitals Birmingham NHS Foundation Trust, Birmingham. UK
- ³ Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham. UK
- 16 ⁴ brainstrust, Cowes, Isle of Wight. UK
- 17 ⁵ Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh. UK
- 18 ⁶ Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford. UK

19

20

BRAIN MATRIX

22 Abstract

23 Introduction

Gliomas are the most common primary tumour of the central nervous system (CNS), with an estimated annual incidence of 6.6 per 100,000 individuals in the USA and around 14 deaths per day from brain tumours in the UK. The genomic and biological landscape of brain tumours has been increasingly defined and, since 2016, the WHO classification of tumours of the CNS incorporates molecular data, along with morphology, to define tumour subtypes more accurately. The Tessa Jowell BRAIN MATRIX Platform (TJBM) study aims to create a transformative clinical research infrastructure that leverages UK NHS resources to support research that is patient centric and attractive to both academic and commercial investors.

31 Methods and analysis

32 The TJBM study is a programme of work with the principal purpose to improve the knowledge of glioma 33 and treatment for glioma patients. The programme includes a platform study and subsequent 34 interventional clinical trials (as separate protocols). The platform study described here is the backbone 35 data-repository of disease, treatment and outcome data from clinical, imaging and pathology data being 36 collected in glioma patients from secondary care hospitals. The primary outcome measure of the platform is time from biopsy to integrated histological-molecular diagnosis using whole genome sequencing and 37 38 epigenomic classification. Secondary outcome measures include those that are process-centred, patient-39 centred and framework-based. Target recruitment for the study is 1000 patients with interim analyses at 40 100 and 500 patients.

41 Ethics and dissemination

42 The protocol was approved by West Midlands - Edgbaston Research Ethics Committee. Participants will be 43 required to provide written informed consent. The results of this study will be disseminated through 44 national and international presentations and peer-reviewed publications.

45 Trial registration number

- 46 ClinicalTrials.gov Identifier: NCT04274283; 18-Feb-2020
- 47 ISRCTN 14218060; 03-Feb-2020
- 48

49 Strengths and limitations of this study

- 50 • The TJBM study is a programme of work, which will improve the knowledge of glioma, and 51 treatment for glioma patients. This platform study is a backbone data-repository of disease, treatment and outcome data from 52 ٠ 53 clinical, imaging and pathology data 54 The TJBM study will aim to provide rapid and accurate molecular diagnosis, a network of clinical ٠ 55 hubs with robust protocols for the collection, processing, analysis and storage of tissue, images, 56 and clinical and quality of life data
- Gliomas occur at all ages and their specific subtype is difficult to predict preoperatively, therefore,
 the patient population eligible for the study is broad but currently excludes <16-year-old patients

BRAIN MATRIX

59 Introduction

60 Gliomas are the most common primary tumour of the central nervous system (CNS), with an estimated 61 annual incidence of 6.6 per 100,000 individuals in the USA (1), which is predicted to rise to 22/100,000 by 62 2035 (2). In 2016, there were 5,250 deaths from brain tumours in the UK i.e., 14 deaths per day (2). 63 Malignant CNS tumours hold the poorest prognosis, and are responsible for the highest estimated number 64 of years of potential life lost (mean 20 years) amongst all cancers (3) and survival trends have remained 65 generally static in comparison to other cancers (4).

66 Gliomas have traditionally been divided into low grade glioma (LGG; WHO I-II) and high-grade glioma (HGG; 67 WHO III-IV) based on integrated classic histological features and molecular biomarkers (5). LGG have an 68 indolent course with patients commonly surviving a decade after diagnosis (6). However, the natural 69 history of many WHO Grade II LGG is progression to HGG. Approximately half of all newly diagnosed 70 gliomas are classified as glioblastoma (GB; WHO IV), the most malignant type of brain cancer. Currently, 71 the GB annual incidence is 3.2 per 100,000 population in the USA. This tumour occurs more frequently with 72 advancing age; ranging from 0.4 per 100,000 population aged 20-34 years, to over 15 per 100,000 73 population aged 75-84 years (1). It is widely recognized that elderly populations are rapidly increasing 74 globally and this will have a significant impact on the burden of GB disease. Despite this, most studies still 75 focus on patients younger than 65 years.

76 The current gold standard treatment for newly diagnosed GB is surgical gross total resection (GTR), 77 followed by radiotherapy with concomitant and adjuvant temozolomide. The aim of treatment is to delay 78 tumour progression and extend overall survival (7). Despite decades of refinement, this approach results 79 in a median survival time of only 12-14 months.

80 Over the last 20 years the genomic and biological landscape of brain tumours has been increasingly defined, 81 refining previous classification systems, unravelling intra- and inter-tumoural heterogeneity and 82 progression, identifying drug targets and potential therapeutic strategies, and better characterising 83 challenges to therapies, such as the blood brain barrier (BBB) and mutational escape. In 2016, the WHO 84 published its classification of tumours of the CNS (5), which for the first time used molecular data, along 85 with morphology, to define tumour subtypes more accurately. This stratification integrated a combination 86 of specific genetic and epigenetic biological characteristics that are changing rapidly as our knowledge 87 evolves (8). In recognition of this rapid evolution of knowledge, 'cIMPACT-NOW' (Consortium to Inform 88 Molecular and Practical Approaches to CNS Tumor Taxonomy – Not Official WHO) (9) was created, with the 89 new WHO 2021 classification representing a consensus opinion based on new insights into the molecular 90 definition of brain tumours from this collaboration (10). As analytical technologies evolve and become 91 more affordable, genome-wide analyses combined with other so-called 'omics' data will lead to further 92 refinement of tumour classification with meaningful impacts on prognosis and choice of therapy. This is 93 the motivation for the TJBM study, which will adopt whole-genome sequencing (WGS) and epigenomic 94 analysis of tumour samples.

95 The TJBM study aims to create a transformative clinical research infrastructure that leverages NHS 96 resources to support research that is patient centric and attractive to both academic and commercial 97 investors. Our approach will be holistic and flexible so that it can rapidly adapt to scientific advances and 98 rigorously evaluate new drugs and technologies. To achieve this, it will establish a research-active network 99 of clinicians and scientists who are well supported by an innovative trial infrastructure to deliver the 100 following:

BRAIN MATRIX

101 •	Rapid and accurate molecular diagnosis ensuring precise classification of tumours and identifying
102	subsets of patients suitable for targeted therapy, by building on the legacy of the 100,000
103	Genomes Project (11).
104 •	A network of clinical hubs resourced to maximise patient recruitment and collect tissue and data.
105 •	Robust protocols for the collection, processing, analysis and storage of tissue, images and clinical
106	and quality of life (QoL) data, building on existing infrastructure such as UK Biobank (12), Medical
107	Research Council (MRC) Brain Banks Network (13), and the CRUK PEACE study (14).
108 •	High-quality biological samples that are fully clinically and radiologically annotated facilitating
109	further biological and radiological research.
110 •	Links to national and international clinical and scientific infrastructure and networks (15); e.g.,
111	Genomics England (GEL), European Network for Rare adult solid Cancer (EURACAN) (16), SIOP-E
112	Brain Tumour Group, and National Cancer Research Institute (NCRI) Groups.
113 •	Access to novel and repurposed drugs and technologies through collaborative partnerships with
114	industry and early phase trials hubs and the structural genomics consortium (www.thesgc.org), to
115	develop novel trials, within and outside, the TJBM infrastructure for testing of therapeutic
116	strategies, including novel agents. As such therapeutic clinical trials will be developed using this
117	infrastructure to maximise efficiency in introducing and rigorously evaluating novel interventions.
118	These will be separate protocols to the TJBM study.
119 •	Long-term sustainability through delivery of clinically and scientifically meaningful outcomes,
120	leveraged investigator-led research grants and an established cost-recovery model for biobanking
121	(17).

122 Methods and analysis

123 Study design

The TJBM study is a programme of work the principal purpose of which is to improve the knowledge of glioma and treatment for glioma patients. The programme will include a platform study and subsequent interventional clinical trials (as separate protocols); Figure 1. This platform study, is the backbone datarepository of disease, treatment and outcome data from clinical, imaging and pathology data to be collected in glioma patients from secondary care hospitals. Figure 2 shows an overview of the platform's study schema.

The study aims to recruit 1000 patients within the UK over 5 years with participants followed up for up to
5 years. An initial 10 UK centres were opened to the TJBM study, as listed in Supplementary Appendix 1,
although further centre expansion is planned. The Standard Protocol Items: Recommendations for
Intervention Trials (SPIRIT) checklist is provided as Supplementary Appendix 2 (18). The World Health
Organization (WHO) Trial Registration Data Set is provided in Supplementary Appendix 3.

135 **Patient and public involvement**

Patient and public involvement and engagement (PPIE) has been integral to this study from its inception. Our patient and public advisors, Helen Bulbeck and Peter Buckle, co-developed the TJBM study by reviewing and refining the protocol and the participant-facing documents. They have provided input into the patient-reported outcome measures and have guided messaging about the study for the community. As members of the Study Management Group (SMG; Supplementary Appendix 1) they continue to assess study conduct, and will contribute to the interpretation and dissemination of study findings through the

BRAIN MATRIX

- 142 PPIE dissemination strategy. This will include presentation of the study findings to identified audiences, the
- 143 best channel for reach, when to communicate, messaging and sensitivities.

144 **Patient selection**

Patients aged ≥16 years with newly diagnosed suspected WHO Grade II-IV glioma, (as evidenced radiologically) suitable for a diagnostic or therapeutic surgical procedure resulting in a tumour sample matched to a blood sample or with progression with known WHO Grade II-IV glioma will be eligible.

- Patients with primary spinal cord tumours, who are receiving active treatment of other malignancy, have contraindications to magnetic resonance imaging (MRI) and/or without standard of care imaging available,
- 150 will be excluded.
- Newly diagnosed patients with suspected WHO Grade II-IV glioma who are subsequently found to have a
 WHO Grade I tumour or non-brain tumour are expected to be a rare occurrence. If this event occurs:
- If it is confirmed as a Grade I tumour, then the patient will remain eligible for the study and will
 continue to be followed up in accordance with the protocol.
- If it is confirmed as a non-brain tumour, then the patient will not remain on the study and no
 further follow-up data will be collected.
- 157 All patients must be able to provide written informed consent for the study.

158 Consent

159 Supplementary Appendix 4 contains exemplar informed consent forms (ICF), with Supplementary Appendix

160 5 the patient information sheets (PIS) and lay summary for the study. The investigator or an appropriately

161 trained delegate must obtain written informed consent for each patient prior to performing any study

162 related procedure. Remote Consent for platform entry is permitted by telephone or video consultation

- 163 instead of face-to-face consultations.
- 164 In addition, to consenting to join TJBM, patients will be required to provide agreement for:
- The collection and analysis of biological samples (e.g., tumour, blood), including access to existing
 and future samples.
- The collection of relevant clinical information, including imaging and pathology.
- The return of clinically relevant results back to the referring clinician.
- The use of, and sharing of data, for research, teaching, commercial and scientific purposes,
 including data sharing through The Brain Tumour Charity's BRIAN (the Brain tumouR Information
 and Analysis Network) database (19).
- The collection of different aspects of health data from the NHS and other Department of Health
 organisations (in addition to medical records) for longitudinal analysis and follow-up.
- The use of clinical data to identify potential clinical trials or other research that they may benefit
 from.
- The sharing of samples for other ethically approved research projects.

177 In addition, and in line with GEL processes and studies such as the 100,000 Genomes Project, optional

178 consent will be taken as to whether the patient would like to receive feedback about the evidence of

179 inherited diseases (both underlying the cause of the cancer and non-cancer causes).

BRAIN MATRIX

- 180 For centres submitting tumour tissue for WGS through the standard of care (SoC) NHS Genomic Medicine
- 181 Service (GMS) pathway in England, an additional GEL consent step is currently required to confirm consent
- 182 at the point of referral for the patient's clinical indication. This additional GEL consent step is performed
- 183 electronically or on paper and can be completed over the phone.

184 Platform assessments and schedule of events

- 185 Platform entry requires baseline clinical data, NIH Stroke Scale (20), weight, and WHO Performance Status
- to be recorded, and then performed again at start and end of concomitant therapy, start and end of
- adjuvant therapy, further surgery and during the five-year follow-up period.
- 188 In addition, QoL questionnaires will be completed at the initiation of concomitant therapy, initiation of
- adjuvant therapy, further surgery and during follow-up. The QoL booklet includes EQ-5D-5L (21), EORTC-
- 190 QLQ-c30 (22), Patient Concerns Inventory (PCI) (23), Patient Global Impression of Change (PGIC) (24), and
- 191 Clinician Global Impression of Change (25).
- 192 The schedule of events in included in Supplementary Appendix 6.

193 Platform study outcome measures

194 The primary outcome measure of the platform is time from biopsy to integrated histological-molecular

- diagnosis (TTMD) as defined as the difference (in days) between date of biopsy and date of WGS and epigenomic classification.
- Secondary outcome measures include those that are process-centred, patient-centred, and framework-based.
- Process-centred secondaries include: time to completion of each node of tissue and imaging pathway;
 tumour and biological sample(s) quality control (QC) status; imaging QC status, and; inter-rater agreement
 of response assessment in neuro-oncology (RANO) (26).
- Patient-centred secondaries include: extent of surgical resection; overall survival time (OS); intracranial
 progression-free survival time (PFS); QoL scores; type of interventions received; type of complications from
 treatments (standard of care) received, and; concordance between initial local radiological diagnosis, local
 pathological diagnosis, and integrated histological-molecular diagnosis.
- Research framework-based secondaries include: samples and images centrally stored; targetable mutation(s) identified; post-mortem sampling consent status and sample collection confirmation, and; number of applications to, and outputs resulting from data repository (including trial proposals both within and outside of the TJBM network).

210 Statistical analysis plan

The target sample size for the study is 1000 patients. The primary remit of TJBM study is to establish a central data repository that will support the development and delivery of precision medicine for all glioma

- 213 patients in the UK. As such, there is no statistical basis behind the choice of target sample size, but this
- 214 number will allow robust assessment of feasibility and subgroup analyses. Sample size for any clinical trials
- that are subsequently linked to the platform will be based on statistical justification.
- A formal interim analysis of the primary outcome measure (TTMD) and any relevant secondaries will be performed after registration and diagnosis of the first 100 patients and after 500 patients. There are no

BRAIN MATRIX

formal stopping rules. Formal analyses of all study outcome measures will be performed once the study
 has completed recruitment (target 1000 patients) and completed the follow up for all registered patients.

The analysis of TTMD will essentially be descriptive. The median TTMD will be reported overall and for each centre, together with the proportion of patients achieving TTMD within 28 days. Graphs of the change in both these summary statistics over time will be used to explore if TTMD changes during the course of the study. All estimates will be accompanied by 95% confidence intervals (CI). The time to completion of each node of tissue and imaging pathway will be reported as medians together with 95% CI, both overall and for

225 each centre. Swimmer plots will be used to depict overall and node level timings for each patient.

For each type of tumour and biological sample, the proportion of sample passing QC and successfully
 undergoing WGS and EC will be reported with 95% CI and similarly for the imaging QC outcome measures.
 Inter-rater agreement of RANO will be assessed through Kendall's coefficient of concordance.

Extent of surgical resection is evaluated from the post-operative MRI scan and is categorised as either; closed biopsy, open biopsy, debulking <50%, subtotal resection 50-90%, near total resection 90-<100%, gross total resection 100%. The extent of surgical resection will be reported as the proportion falling into each category together with 95% CI.

OS is defined as the time from date of diagnosis to the date of death with patients who are alive at the time of analysis censored at the date last seen in clinic. Intracranial PFS time is defined as the time from date of registration to the earliest of date of intracranial progressive disease or death from disease. The date of an event is defined as the earliest confirmation of progression by radiological assessment, clinical symptoms or multidisciplinary team (MDT). Patients without progression at the time of analysis will be censored at the date last seen in clinic.

OS and intracranial PFS will be analysed and plotted using the Kaplan-Meier method. Median times with
 corresponding 95% CI will be reported together with rates at 1, 2 and 5 years. Multivariable survival
 regression modelling will be used to explore prognostic factors, including, but not limited to, WHO 2021
 classification, age, tumour volume, stage, methylation and mutation status.

Longitudinal measures of QoL will be generated from the QoL questionnaire according to the questionnaire-specific algorithms for scoring. The analysis of longitudinal QoL scores will essentially be descriptive. For each of the multiple QoL scores generated from the different questionnaires, the means, medians or proportions (as appropriate) will be plotted over time together with 95% CI. These repeated measures over time may be modelled, if appropriate, with a linear or more flexible mixed model that takes account of the within-subject correlation and will allow exploration of factors associated with the outcome.

Details of the type of intervention received and complications (e.g., surgical wound infection) relating to standard of care treatments received will be monitored and recorded throughout the follow-up period and reported descriptively as frequencies and associated percentages. In relation to initial local logical diagnosis, local pathological diagnosis and integrated histological-molecular diagnosis, any difference between the tiers of diagnoses will be highlighted and categorised as: discordant; agreed; refined and reported descriptively as frequencies and associated percentages.

255 Confirmation of central storage of images and material, relevant targetable mutations identified by WGS 256 and epigenomic classification, and receipt of post-mortem consent forms with confirmed central storage

257 of samples will be recorded and reported descriptively.

BRAIN MATRIX

258 Planned subgroup analyses of outcome measures include: IDH mutated and wildtype tumours; residual

enhancing disease (RED; none, operable, inoperable); methylated and un-methylated tumours; age groups;

260 types of diagnosis (WHO 2021 criteria only, epigenetic classification only, WGS analysis only, integrated

261 diagnosis comprising all three); performance status; sex, and; biomarkers that emerge during the study

262 (either discovered in the TJBM study or reported in the literature) that are deemed relevant after review

263 by the Scientific Advisory Board (SAB).

264 Biological samples

265 Sample collection

Biological samples will be collected at each participating site following agreed protocols and guidance from
 the central biospecimen coordination centre (Oxford BRAIN MATRIX Laboratory). The aim is to build as
 much as possible on existing GEL infrastructure and pathways. The funded pathway is represented in Figure
 3.

Fresh tissue for TJBM must be frozen in liquid nitrogen and stored until shipment to the Oxford BRAIN
 MATRIX Laboratory. Matched 'germline' DNA from white blood cells is required for the detection of
 somatic variants for paired blood/tumour WGS. This should be collected as per standard GEL protocols.
 Ideally, it should be collected prior to or at the time of first surgery. The blood sample(s) must be shipped

together with the frozen tissue of the patient to the Oxford BRAIN MATRIX Laboratory.

For patients who are not undergoing surgery and have available tumour samples from previous tumour surgery, blood should be collected and sent to the Oxford BRAIN MATRIX Laboratory along with their tumour samples.

278 For participants unable to donate a blood sample, a saliva sample is an acceptable alternative.

Where possible, it is intended to collect blood samples for liquid biopsies of the tumour (e.g., trackingcirculating tumour cell free (cft)DNA within the blood). Samples should ideally be collected at the time of

281 operation, before the neurosurgeon performs any incision, ideally in theatres or the anaesthetics room just

before any biopsy. Where feasible further blood samples should be collected at the following key treatmentmilestones:

- 284 1. At first post-operative MRI
- 285 2. Initiation of concomitant therapy (if applicable).
- 286 3. The end of concomitant therapy (if applicable).
- 287 4. Initiation of adjuvant therapy (if applicable).
- 288 5. The end of adjuvant therapy (if applicable).
- 289 6. The time of objectively measured progression.
- 290 7. During the palliative phase if a post-mortem has been agreed.

291 Where cerebrospinal fluid (CSF) is available for the patient, this should also be submitted.

Participating sites should follow the CRUK PEACE study protocol for post-mortem neurological tissue donation. The aim of post-mortem tissue donation is to enable research into:

- 294 1. The clonal evolution of the glioma after emergence of therapy resistance.
- 295 2. Tumour host-interaction at the whole brain level.
- 296 3. The effect of radio-chemotherapy on normal brain.

BRAIN MATRIX

4. The interaction between the glioma and non-CNS organs (e.g., immune system in the cervical lymph nodes).

299 Sample analyses

Matched tumour/blood samples collected at first surgery are the most important samples of the TJBM study as these determine the initial integrated histological-molecular diagnosis. Following histological QC, the Oxford BRAIN MATRIX Laboratory will perform DNA extraction and QC; an aliquot will be sent to the Illumina Centre in Cambridge for WGS, and one used for EPIC methylation array at the Wellcome Trust Centre for Human Genetics in Oxford. Remaining DNA and unused tissues will be stored at the BRAIN MATRIX Biorepository.

Raw WGS data will be maintained in the GEL Data Research Environment, where it can be accessed and re analysed by data scientists at the submitting NHS Genomic Laboratory Hub or any qualifying TJBM
 approved researcher. Sample data not generated by GEL will be consolidated in established bioinformatics
 hubs of the University of Oxford (Big Data Institute/Weatherall Institute for Molecular Medicine).

Data files on the Illumina 850k EPIC BeadChip analysis will be uploaded to the 'Heidelberg Classifier' hub at
the German Cancer Centre in Heidelberg (27). This will generate an automated classifier report which will
be stored at the Oxford BRAIN MATRIX Lab. Raw array data will be made available via the Oxford BRAIN
MATRIX Laboratory.

Matched histological sections will be digitised at the Oxford BRAIN MATRIX Laboratory resulting in linked genomic data, which will initially be stored in Oxford. As the study evolves, we will aim to capture digital histological data from the material kept at the local neuropathology centre. The Oxford BRAIN MATRIX hub is working with CRUK-established data visualisation platforms, such as those developed for S:CORT (Colorectal Cancer) (28) and based on international open access platforms (such as cBioPortal (29)).

319 The BRAIN MATRIX neuropathology and genomics team will generate an integrated report (histology, WGS, 320 Heidelberg Classifier) for each case in consultation with the local neuropathology team. The primary BRAIN 321 MATRIX report will comprise the formal routine GEL WGS report (germline and tumour) and Heidelberg 322 Classifier report and integrate this with the histological and molecular report issued by the recruiting site. 323 It is anticipated that a local histological and molecular diagnosis using immunohistochemical surrogate 324 markers and targeted genetic analyses will be available before WGS and Illumina EPIC BeadChip data are 325 returned to the Oxford BRAIN MATRIX Lab. When available, the BRAIN MATRIX neuropathology and 326 molecular genetics team will conduct a virtual MDT with the referring site to ensure all relevant information 327 will be incorporated in the final BRAIN MATRIX diagnostic report. Variant calling and classifier outputs will 328 be determined by the practice at the GEL/Illumina Centre and the version of the Heidelberg Classifier 329 algorithm active at the time of sample analysis.

Where relevant germline data is identified, local sites should facilitate local genetic referral as per otherGEL study protocols.

332 Imaging data

Pseudo-anonymised longitudinal clinical imaging (MRI) for each patient will be collected and stored at a central imaging hub overseen by the Edinburgh Imaging Hub. Disease response assessment will be performed by practicing UK neuro-radiologists with a neuro-oncology interest via the Edinburgh Imaging Platform and additional analyses undertaken through the University of Edinburgh image analysis laboratory with permitted partners.

BRAIN MATRIX

As per patient standard of care, it is expected that imaging will be performed pre- and post-operatively, for
 radiotherapy planning, following any chemoradiation, and as per follow-up determined by the managing
 MDT and/or if clinical concerns are raised regarding disease progression.

341 Pragmatic MRI protocols will be conducted as per standard of care MRI protocols and timing following 342 diagnosis and as such will be informed by the National Institute for health and Care Excellence (NICE) 343 guidelines from 2018 (30), in line with the recent British Society of Neuroradiologists (BSNR) imaging 344 guidance (31), which is itself an implementation of the Brain Tumour Imaging Protocol proposed by 345 Ellingson et al. (32). Where additional advanced imaging is performed this is also encouraged to be 346 submitted to the Edinburgh Imaging Hub and will be catalogued to permit any relevant subsequent 347 analysis. Biopsy location imaging should also be submitted, and standard operating protocols for the major 348 neuro-navigation systems followed. Radiotherapy planning imaging will also be submitted.

The RANO assessments will be performed through a secure web portal provided by QMENTA Inc. There will be an ongoing 10% re-read to assess inter-rater agreement. It is anticipated that RANO reports will be provided within 2 weeks (10 working days) of successful transfer of imaging requiring assessment. RANO reports will categorise response where possible into Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD). In cases of diagnostic uncertainty, potential or provisional outcomes may be recorded, allowing progression events to be backdated to the correct time point should subsequent imaging be confirmatory.

356 Adverse events reporting

There are no study treatments within the TJBM study. Blood sampling and completion of QoL questionnaires are the only procedures that patients undergo additional to usual care. Therefore, it is not anticipated that there will be adverse events related to participation in this study. Only severe adverse events (SAEs) relating to those additional procedures will be reported as per Common Terminology Criteria for Adverse Events (CTCAE) version 4 (33) and as defined in Supplementary Appendix 7. The reporting period is from the date of informed consent to death.

363 Data management

Case report forms will be entered online via a secure web-based portal. Authorised staff at sites will require an individual secure login username and password to access this online data entry system. Paper CRFs will be available for backup only and must be completed, signed/dated and returned to the BRAIN MATRIX Study Office by the investigator or an authorised member of the site research team. Data reported on each CRF should be consistent with the source data or the discrepancies should be explained. If information is not known, this must be clearly indicated on the CRF. All missing and ambiguous data will be queried. All sections are to be completed.

All study records must be archived and securely retained for at least 25 years. No documents will be destroyed without prior approval from the sponsor, via the central Study Office. On-site monitoring will be carried out as required following a risk assessment and as documented in the Quality Management Plan. Any monitoring activities will be reported to the central BRAIN MATRIX Study Office and any issues noted will be followed up to resolution. BRAIN MATRIX will also be centrally monitored, which may trigger additional on-site monitoring. Further information regarding data management is provided in the study protocol.

BRAIN MATRIX

The CRCTU will hold the final study dataset and will be responsible for the controlled sharing of anonymised data with the wider research community to maximise potential patient benefit while protecting the privacy and confidentiality of study participants. Data anonymised in compliance with the Information Commissioners Office requirements, using a procedure based on guidelines from the Medical Research Council (MRC) Methodology Hubs, will be available for sharing with researchers outside of the trials team within 12 months of the primary publication.

384 Trial organisation structure

The University of Birmingham will act as single sponsor to this multi-centre study: Support Group, Aston Webb Building, Room 119, Birmingham, B15 2TT. Email: <u>researchgovernance@contacts.bham.ac.uk</u>). The study is being conducted under the auspices of the CRCTU, University of Birmingham according to their local procedures.

The Chief Investigator, Co-investigators, Trial Management Team Leader, Senior Trial Coordinator, Trial Coordinator, Lead and Trial Statistician, Trial Monitor and patient representatives will form the Study Management Group (SMG; current membership is listed in Supplementary Appendix 1). The SMG will be responsible for the day-to-day conduct of the TJBM study, meeting at regular intervals (e.g., at least every three months), or as required, usually by teleconference. They will be responsible for the set-up, promotion, on-going management of the study, the interpretation of the results and preparation and presentation of relevant publications.

396 Selected findings of clinical significance will be presented to the Scientific Advisory Board (SAB), which as a 397 minimum will include the Chief Investigator, an oncologist, a pathologist, and a molecular biologist for a 398 combined review of the molecular findings in context. The SAB may suggest amendments that will be 399 incorporated into a SAB Report, which will be sent to the Executive Oversight Committee (EOC); current 400 SAB and EOC membership is listed in Supplementary Appendix 1. Possible re-testing/further testing may 401 be required, as a result of SAB feedback. Guided decision-making tools that review results in the context 402 of the literature and clinical experience will be piloted within the SAB. The SAB will also evaluate research 403 and study proposals, manage data/tissue requests, and will report back to the EOC regarding any proposals 404 or changes which they may suggest.

The overarching remit of the EOC is to mandate, including timeframe and deliverables, the responsibility of the SAB and to take responsibility of horizon scanning to enable the incorporation of new interventional arms. They will oversee the overall study management of both the platform and any standalone interventional trials. They will also liaise with other trial units and pharma stakeholders as well as funders, charities, study sponsors, and policymakers and liaise with the BRIAN team. A quarterly EOC Report will be disseminated to all stakeholders that will demonstrate the performance metrics of each clinical site. In addition, the use of all samples given to external researchers via the SAB will be included in the report.

412 **Confidentiality**

Confidential information collected during the study will be stored in accordance with the General Data Protection Regulation (GDPR) 2018. As specified in the patient information sheet (PIS) and with the patients' consent, patients will be identified using only their date of birth and unique study ID number. Authorised staff may have access to the records for quality assurance and audit purposes. The BRAIN MATRIX Study Office maintains the confidentiality of all patients' data and will not disclose information by which patients may be identified to any third party other than those directly involved in the treatment of

BRAIN MATRIX

- the patient and organisations for which the patient has given explicit consent for data transfer (e.g.,
- 420 laboratory staff).

421 Trial status

422 Recruitment for the study opened in Nov-2020 and recruitment is expected to last for 5 years.

423 Ethics and dissemination

The study will be performed in accordance with the recommendations guiding physicians in biomedical research involving human subjects, adopted by the 18th World Medical Association General Assembly, Helsinki, Finland and stated in the respective participating countries laws governing human research, and Good Clinical Practice. The protocol was initially approved on 18-Feb-2020 by West Midlands - Edgbaston

428 Research Ethics Committee; the current protocol (v3.0) was approved on 15-Jun-2022.

429 A meeting will be held after the end of the study to allow discussion of the main results among the 430 collaborators prior to publication. The results of this study will be disseminated through national and 431 international presentations and peer-reviewed publications.

432 Manuscripts will be prepared by the SMG and authorship will be determined by mutual agreement.

433 **Discussion**

434 Justification for patient population

The main aim of the TJBM study is to test the hypothesis that comprehensive genomic and epigenomic profiling of gliomas is feasible in a timely manner in the UK, and that the results improve stratification of

437 patients for next generation (targeted) therapies, ultimately improving outcomes and QoL.

Gliomas occur at all ages and their specific subtype is difficult to predict preoperatively. Therefore, the
patient population eligible for the TJBM study is broad. It includes any patient who on preoperative
assessment is suspected to have a diffuse glioma, or where a diffuse glioma remains a credible differential
diagnosis, as established by the multidisciplinary team at the recruiting site.

- 442 Recruitment is also open to patients with diffuse or atypical gliomas who had a biopsy before the launch 443 of the TJBM study. This approach ensures that:
- Patients with slow-growing diffuse gliomas that evolve over many years (oligodendrogliomas) may
 benefit from one or more of the clinical trials developed as part of the TJBM study and sample
 collection at tumour progression.
- Patients who potentially benefit most from comprehensive molecular diagnostics are not missed,which often are those with rare or atypical variants of glioma based on current diagnostics (34).
- The infrastructure for children with brain tumours in the UK is different to that of adults with epigenomic classification regularly used and with WGS shortly to be made available for all children with cancer. Thus, the challenges and opportunities are different for paediatric patients. Nevertheless, it is intended that children will be included within the TJBM study wherever appropriate. The recruitment of children and
- 453 adolescents into the TJBM study will be coordinated with the UK's paediatric oncology expert group(s).

BRAIN MATRIX

454 Justification for methodology

Neuroimaging with MRI plays a central role in the initial diagnosis and treatment stratification, surgical and
 radiotherapy planning and assessment of disease response and progression in glioma.

457 Potential participants will have undergone MRI as part of a diagnostic work-up and an intracranial mass 458 identified. As per current clinical practice, expert neuroradiological review will indicate glioma as the likely 459 diagnosis, and a plan for treatment will be made by the relevant regional MDT meeting. Those with 460 suspected glioma on MRI who are to undergo surgery and are otherwise eligible for the TJBM study will be 461 approached. A proportion of these lesions that are subsequently diagnosed as types of brain tumours other 462 than glioma will inevitably be included. They will not be included in the main analysis; however, data from 463 these will be stored for additional research into those less common tumours which can be challenging to 464 diagnose from imaging alone.

At the time of surgery, neuro-navigation will be used to capture the location of each biopsy taken for diagnosis and further molecular characterisation within the TJBM study. This will aid with subsequent analysis of tumour molecular markers and heterogeneity in the context of radio-genomics – a recent development in cancer imaging for assessment of disease in the personalised medicine era employing machine learning and artificial intelligence approaches (32).

470 Early post-operative imaging for suspected HGG, including pre- and post-contrast T1-weighted MRI, is 471 currently recommended within 72 hours of surgery to minimise the presence of non-neoplastic 472 enhancement. This imaging will be captured to permit eventual assessment of extent of resection, or the 473 volume of residual enhancing disease, important prognostic factors for glioma. Subsequent to this, any 474 additional imaging for radiotherapy planning, including computerised tomography (CT), will be captured. 475 Under the most recent response assessment in neuro-oncology (34) recommendations for HGG from 2017, 476 this is recommended as the baseline for assessing treatment response (32).

All imaging will receive primary radiological reports at the local site as per current standard clinical practice.
To deliver the imaging outcome requirements for clinical trials, centralised RANO reads will be delivered
by a core group of UK Consultant neuro-radiologists with a subspecialty interest in neuro-oncology imaging
from TJBM study sites. Radiotherapy planning data in the form of dose distribution maps and associated
data will be integrated into the imaging database to permit subsequent analysis of spatiotemporal
response patterns of different glioma-treatment combinations in light of received radiation dose.

483 Local radiological reporting will inform clinical decision making for individual patients. Central image 484 analysis will provide resilient standardised assessment to meet internationally-accepted standards which 485 are suitable for peer-reviewed publication and are accepted by major regulatory approval bodies. All 486 relevant pre-operative and subsequent imaging will be identified for pseudonymisation and uploaded to 487 the BRAIN MATRIX Imaging Platform in Edinburgh. This will be achieved through a dedicated online secure 488 portal, with alternative secure online and physical transmission pathways available for redundancy. The 489 accrued imaging data will form a core resource that will be leveraged for future imaging and clinical 490 radiological research. The platform can also provide the basis for additional imaging studies within non-491 standard of care imaging and advanced techniques, which would be separately funded and detailed in their 492 respective project documentation.

BRAIN MATRIX

493 Justification for tissue collection

Historical approaches to brain tumour tissue collection in formaldehyde and paraffin are not currently fully
compatible with modern genomic technologies, which require frozen tissue. This is why the collection of
fresh frozen (FF) material is essential for the TJBM study. Pairing with non-neoplastic, so-called germline
DNA, is also essential for confident calling of somatic variants in the tumour. Germline DNA analysis will
also provide novel data on genetic risk for glioma predisposition.

Blood plasma, where possible, will be collected to facilitate future analysis of cftDNA. This technology is
still in its infancy; however, it is clear that non-invasive, real-time monitoring of tumour evolution will
become feasible in the next 5-10 years (35). Similarly, where available for the patient, CSF will be submitted.

502 Post-mortem tissue banking via the CRUK PEACE and MRC Brain BioLink projects will allow us to study the 503 glioma-brain interface, extent of spatial tumour heterogeneity, genomic signature of the treatment 504 resistant tumour clones, and effect of treatments on normal brain. Systematic post-mortem brain banking 505 for research into adult gliomas does not currently exist in the UK.

506 Justification for molecular diagnostics

All TJBM study baseline diagnoses will follow the new WHO classification of tumours of the CNS from 2021 to achieve an integrated histological-molecular diagnosis for diffuse gliomas (10). This is achieved with a combination of immunohistochemical surrogate markers and – in most instances – targeted or panel sequencing for relevant hotspot mutations, or cytogenetics (7). Only in exceptional circumstances unbiased 'omics' approaches are used, such as the epigenomic 'Heidelberg Classifier' (34). Further, any diagnostic approach may differ between centres in the UK, making analyses of cohorts pooled from different sites difficult.

514 The new WHO 2021 classification represents a consensus opinion based on new insights into the molecular 515 definition of brain tumours from cIMPACT-NOW. cIMPACT-NOW updates are not intended to supplant the 516 existing WHO classification, but to provide possible guidelines for practicing diagnosticians and future WHO 517 classification updates. It is clear from the first iterations of cIMPACT-NOW that any progress is driven by 518 next generation ('omics') molecular analysis, not by standard or targeted analyses. This insight underpins 519 the selection of molecular analytical tools for the TJBM platform, namely, combined paired (blood-tumour) 520 WGS DNA analysis integrated with the epigenomic 'Heidelberg Classifier' (34). To achieve this, the TJBM 521 study will build on the experience and UK infrastructure of the 100,000 genomes project led by GEL, which 522 introduced WGS pathways into clinical practice. Early results from WGS in non-brain cancer patients 523 suggest that virtually all patients could be mapped to existing or potential targeted therapies (36). 524 Prospective large-scale paired WGS sequencing studies in diffuse glioma patients have not been done; 525 however, experience from other brain tumours such as medulloblastoma, suggest that analysis of WGS 526 data will provide new insights into glioma subtype diversity, including alterations in specific non-coding 527 regulatory elements not evident from non-WGS genomic approaches (37). WGS data will capture all 528 currently known relevant variants and uncover novel variants relevant for a better understanding of 529 tumour evolution and response to treatment. WGS and epigenomic analyses are highly complementary 530 genomic approaches (37): WGS will establish all potentially actionable mutations and epigenomic 531 classification will establish an unbiased score for the precise classification of the glioma (34). Neither can 532 be achieved with conventional targeted sequencing approaches. Importantly, the epigenomic classification 533 by novel DNA methylation-based 'Heidelberg Classifier' has been shown to fundamentally alter clinical 534 diagnoses and histological grades in >10% of biopsies, leading to changes in therapy (34). Moreover, the 535 epigenomic array technology provides genomic copy number variant data, which in theory can also be

BRAIN MATRIX

inferred from WGS data. However, pipelines for this type of analysis from WGS data are just evolving and
it is predicted that comparative analysis of WGS and Illumina's EPIC BeadChip data will be bioinformatically
highly valuable. Finally, WGS and the EPIC array raw data will form a unique source for researchers who
will be able to access this data together with all clinical, imaging and histological data. Creating a relatively
future-proof, quality-controlled research infrastructure is one of the main aims of the TJBM study, in
addition to establishing feasibility of timely genomic diagnosis in the NHS setting.

the TJBM study is more than paired tumour/blood WGS and EPIC array analysis. As the former is being rolled out in the NHS in England, the BRAIN MATRIX molecular neuropathology team will work with GEL and other stakeholders (including industry) to explore the next-generation of tissue analytics (such as longread sequencing and mass spectrometry). This will result in a unique, prospectively acquired dataset that will enable researchers to integrate data analysis across modalities and with outcomes and treatment response.

548 Justification for patient outcome and quality of life

549 Clinical trials require prospective collection of clinical data to Good Clinical Practice (GCP) standards. This 550 platform will develop the infrastructure for the collection of this, enabling streamlined patient recruitment 551 into clinical trials. Evaluation of treatments and associated complications across patients will give an 552 accurate measure of adverse events associated with current standard of care treatment in practice in the 553 UK.

554 Maximising QoL for patients with diffuse glioma is important particularly given its poor prognosis; 555 therefore, standardised measures of QoL will be collected. In adults these have been selected for their 556 standardisation and ease of use and have been reviewed with input from Patient Public Involvement (PPI) 557 representatives. It is intended that in the future integration with The Brain Tumour Charity's BRIAN project 558 (REC Reference: 18/SC/0283) (19) will allow further understanding of patient reported outcome measures.

559

560 **Contributors**

- 561 CW (Chief Investigator and first author): conception and design of the study, drafting and review of paper.
- 562 JS: trial management team leader, study design, drafting and review of paper.
- 563 AP: Study Biostatistician, study design, drafting and review of paper.
- 564 RM: senior trial coordinator, review of paper.
- 565 VW: principal investigator (Birmingham), review of paper.
- 566 UP: neuropathologist (Birmingham), study design, review of paper.
- 567 HB: patient and public representative, study design, review of paper.
- 568 JA: study design, review of paper.
- 569 RS: design of the study, review of paper.
- 570 GT: conception and design of the study, review of paper.

BRAIN MATRIX

- 571 AM: conception and design of the study, review of paper.
- 572 OA: conception and design of the study, review of paper.
- 573 LB: Lead Biostatistician, design of study, drafting and review of paper.

574 **Funding**

575 This is an Investigator-initiated and Investigator-led study funded by The Brain Tumour Charity (GN-576 000580) and Genomics England with funding from INNOVATE UK. This study has been adopted into the 577 NIHR CRN Portfolio.

- 578 Staff at the CRCTU are also supported by core funding grants from Cancer Research UK (C22436/A25354).
- 579 JA is funded by an NIHR Academic Clinical Lectureship, with previous funded from a Cancer Research UK 580 Clinical Trials Fellowship.
- This study was supported by Experimental Cancer Medicine Centres (ECMC) funding (Ref. 25127) and by
 the ECMC Network.

583 Role of funders and sponsor

Neither the sponsor nor funders had any role in study design, data collection, data analysis, data
interpretation or writing of the report. The corresponding author had full access to all the data in the study
and had final responsibility for the decision to submit for publication.

587 **Competing interests**

588 All other authors declare no competing interests.

589 Acknowledgements

590 We would like to thank our PPI representative, Peter Buckle who, with Helen Bulbeck, has been 591 instrumental in making sure the patients' voice has been heard and incorporated into this study protocol. 592 In addition, we thank staff past and present from the CRCTU, University of Birmingham including Clive 593 Stubbs, Richard Fox, Dr Sarah Bowden, Prof. Christina Yap, Dr Siân Lax and Dr Louisa Jeffery, and Hannah 594 Brooks at the University of Oxford for contributions to the protocol and paper.

595 **References**

Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary
 Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17
 Suppl 4:iv1-iv62.

 599 2. Cancer Research UK. Brain, other CNS and intracranial tumour statistics [Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/brainother-cns-and-intracranial-tumours.

6023.Rouse C, Gittleman H, Ostrom QT, Kruchko C, Barnholtz-Sloan JS. Years of potential life lost for brain603and CNS tumors relative to other cancers in adults in the United States, 2010. Neuro Oncol. 2016;18(1):70-7.

6044.Rachet B, Mitry E, Quinn MJ, Cooper N, Coleman MP. Survival from brain tumours in England and Wales605up to 2001. Br J Cancer. 2008;99 Suppl 1:S98-101.

BRAIN MATRIX

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016
World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta
Neuropathol. 2016;131(6):803-20.

609 6. Sanai N, Chang S, Berger MS. Low-grade gliomas in adults. J Neurosurg. 2011;115(5):948-65.

510 7. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus
511 Concomitant and Adjuvant Temozolomide for Glioblastoma. New England Journal of Medicine.
512 2005;352(10):987-96.

- 613 8. Weller M, Wick W, Aldape K, Brada M, Berger M, Pfister SM, et al. Glioma. Nature Reviews Disease 614 Primers. 2015;1(1):15017.
- 615 9. The International Society of Neuropathology. cIMPACT-NOW 2019 [Available from: 616 http://www.intsocneuropathol.com/2019/03/cimpact-now/.

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification
of Tumors of the Central Nervous System: a summary. Neuro-Oncology. 2021;23(8):1231-51.

11. 100,000 Genomes Pilot on Rare-Disease Diagnosis in Health Care — Preliminary Report. New England
 Journal of Medicine. 2021;385(20):1868-80.

621 12. UK Biobank 2022 [Available from: <u>https://www.ukbiobank.ac.uk/</u>.

622 13. MRC Brain Banks Network [Available from: <u>https://directory.biobankinguk.org/Profile/Biobank/GBR-</u>
 623 <u>1-34</u>.

The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study 2016 [Available from:
 <u>https://clinicaltrials.gov/ct2/show/NCT03004755</u>.

Aldape K, Amin SB, Ashley DM, Barnholtz-Sloan JS, Bates AJ, Beroukhim R, et al. Glioma through the
 looking GLASS : Molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. Neuro oncology. 2018;20(7):11.

629 16. EURACAN. European Network for Rare adult solid Cancer [Available from: http://euracan.ern-net.eu/.

630 17. Tariffs Tissue 2021 Medical Research Council. for Brain [Available from: 631 https://webarchive.nationalarchives.gov.uk/ukgwa/20210903230131/https://mrc.ukri.org/research/facilities-632 and-resources-for-researchers/brain-banks/tariffs-for-brain-tissue/.

633 18. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and
634 elaboration: guidance for protocols of clinical trials. BMJ : British Medical Journal. 2013;346:e7586.

- 635 19. The Brain Tumour Charity. BRIAN [Available from: <u>https://www.thebraintumourcharity.org/living-</u> 636 <u>with-a-brain-tumour/brian/</u>.
- Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, et al. Improved reliability of the NIH Stroke
 Scale using video training. NINDS TPA Stroke Study Group. Stroke. 1994;25(11):2220-6.
- 639 21. Group TE. EuroQol a new facility for the measurement of health-related quality of life. Health Policy.
 640 1990;16(3):199-208.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization
for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical
Trials in Oncology. Journal of the National Cancer Institute. 1993;85(5):365-76.

Rogers SN, El-Sheikha J, Lowe D. The development of a Patients Concerns Inventory (PCI) to help reveal
patients concerns in the head and neck clinic. Oral Oncol. 2009;45(7):555-61.

Guy W, National Institute of Mental H, Psychopharmacology Research B, Early Clinical Drug Evaluation
P. ECDEU assessment manual for psychopharmacology. Rockville, Md.: U.S. Dept. of Health, Education, and
Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of
Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.

Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice.
Psychiatry (Edgmont). 2007;4(7):28-37.

BRAIN MATRIX

- Chukwueke UN, Wen PY. Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical
 trials and clinical practice. CNS Oncol. 2019;8(1):CNS28-CNS.
- 654 27. Heidelberg Classifier. The platform for next generation neuropathology [Available from: 655 <u>www.molecularneuropathology.org/mnp</u>.

S:CORT: Colorectal Cancer Detection & Diganosis Novel Treatments 2022 [Available from:
 <u>https://www.cancer.ox.ac.uk/research/networks/scort</u>.

- 658 29. cBioPortal for Cancer Genomics [Available from: https://www.cbioportal.org/.
- 65930.National Institute for Health and Care Excellence. Brain tumours (primary) and brain metastases in over66016s 2018 [updated 29-Apr-2022. Available from: https://www.nice.org.uk/guidance/ng99.
- British Society of Neuroradiologists. Core imaging protocol for brain tumours 2018 [Available from:
 <u>https://bsnr.org.uk/wp-content/uploads/2021/11/bsnrstandardsbraintumour.pdf</u>.
- 663 32. Ellingson BM. Radiogenomics and Imaging Phenotypes in Glioblastoma: Novel Observations and 664 Correlation with Molecular Characteristics. Current Neurology and Neuroscience Reports. 2014;15(1):506.

66533.Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE),666Version4.032010[Availablefrom:667https://ctep.cancer.gov/protocoldevelopment/electronic applications/ctc.htm#ctc 40.40.from:

668 34. Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, et al. DNA methylation-based 669 classification of central nervous system tumours. Nature. 2018;555:469.

67035.De Rubis G, Rajeev Krishnan S, Bebawy M. Liquid Biopsies in Cancer Diagnosis, Monitoring, and671Prognosis. Trends in Pharmacological Sciences. 2019;40(3):172-86.

Schuh A, Dreau H, Knight SJL, Ridout K, Mizani T, Vavoulis D, et al. Clinically actionable mutation profiles
in patients with cancer identified by whole-genome sequencing. Cold Spring Harb Mol Case Stud.
2018;4(2):a002279.

67537.Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. The whole-676genome landscape of medulloblastoma subtypes. Nature. 2017;547:311.

677

678 Figure Legends

679 Figure 1: Overview of the Tessa Jowell BRAIN MATRIX Programme

The Tessa Jowell BRAIN MATRIX Platform (TJBM) study will collect and integrate clinical, pathological, advanced molecular, imaging, quality of life, treatment and outcome data. The platform may provide data directly or support identification of eligible patients to clinical trials, within and outside the TJBM study programme. If eligible, patients may be enrolled in multiple add-on studies. Through consent and with strong governance processes, anonymised or pseudonymised data may be shared with other relevant organisations or studies within and outside the programme.

686

687 Figure 2: The Tessa Jowell BRAIN MATRIX Platform study schema

688 The study schema for the Tessa Jowell BRAIN MATRIX Platform study.

BRAIN MATRIX

690 Figure 3: The Tessa Jowell BRAIN MATRIX Platform study sample and data flow

691 pathways

- The sample and data flow pathways within the Tessa Jowell BRAIN MATRIX Platform (TJBM) study.
- *TJBM sites in England are encouraged to route all samples through their local NHS GMS GLH, however, if
 this pathway is not yet activated or GEL consent cannot be obtained, the TJBM Study Office can facilitate
- 695 the processing of samples through an alternative NHS GMS GLH or via the GEL Research pathway.
- 696 GEL, Genomics England; GLH, Genomic Laboratory Hub; GMS, Genomic Medicine Service; GTAB, Genomics
- 697 Tumour Advisory Board; NHS, National Health Service; WGS, Whole Genome Sequencing.

698

699 Additional Files

Supplementary Appendix 1: Tessa Jowell BRAIN MATRIX Platform Study Investigators & Committee Membership

Principal Investigators, Study Management Group (SMG), Executive Oversight Committee (EOC) andScientific Advisory Board (SAB).

704

Supplementary Appendix 2: The Tessa Jowell BRAIN MATRIX Platform study SPIRIT Checklist

A completed Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) checklist for the
 Tessa Jowell BRAIN MATRIX Platform study protocol.

709

Supplementary Appendix 3: The Tessa Jowell BRAIN MATRIX Platform study World Health Organization Trial Registration Data Set

The World Health Organization (WHO) trial registration data set for the Tessa Jowell BRAIN MATRIXPlatform study.

714

Supplementary Appendix 4: The Tessa Jowell BRAIN MATRIX Platform study informed consent form

717 The informed consent form for the Tessa Jowell BRAIN MATRIX Platform study.

BRAIN MATRIX

Supplementary Appendix 5: The Tessa Jowell BRAIN MATRIX Platform study lay summary and patient information sheet

721 The lay summary and patient information sheet for the Tessa Jowell BRAIN MATRIX Platform study.

722

Supplementary Appendix 6: The Tessa Jowell BRAIN MATRIX Platform study schedule of events

725 Patient schedule of events for the Tessa Jowell BRAIN MATRIX Platform study.

726

727 **Supplementary Appendix 7: Definition of adverse events**

728 Definitions of adverse events used for the Tessa Jowell BRAIN MATRIX Platform study.



Newly diagnosed patient with suspected WHO grade 2-4 glioma and suitable for a diagnostic or therapeutic surgical procedure resulting in tumour sample matched to a blood sample

(Stereotactic biopsy, open biopsy, sub-total resection or gross total resection)

Patient with progression with known WHO Grade 2-4 glioma

(Those with available frozen tumour will be prioritised)



All cases and non-NHS pathway:

Tissue and blood sample sent to the Oxford BRAIN MATRIX Laboratory for biobanking, biofluid analysis and complementary multiomics NHS GMS pathway:

Tissue and blood sample sent via GLH for WGS and EPIC methylation analysis Imaging sent to the Edinburgh Imaging Hub Follow up information collected for up to 5 years

Molecular/Genomic Tumour Board discussion and feedback of results

